BioScrip Inc. (NASDAQ:BIOS)’s share price was up 1.9% during trading on Thursday . The stock traded as high as $2.70 and last traded at $2.65, with a volume of 308,750 shares. The stock had previously closed at $2.60.

Separately, Zacks Investment Research raised BioScrip from a “sell” rating to a “hold” rating in a research report on Wednesday, March 9th.

The stock’s 50-day moving average price is $2.60 and its 200 day moving average price is $2.20. The firm’s market cap is $184.33 million.

BioScrip (NASDAQ:BIOS) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.05. The company earned $238.50 million during the quarter, compared to analysts’ expectations of $232.38 million. The company’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.17) earnings per share. On average, equities research analysts anticipate that BioScrip Inc. will post ($0.20) earnings per share for the current year.

In other news, Director David W. Golding bought 12,500 shares of the company’s stock in a transaction on Friday, June 17th. The shares were bought at an average cost of $2.48 per share, with a total value of $31,000.00. Following the transaction, the director now directly owns 42,500 shares in the company, valued at approximately $105,400. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Coliseum Capital Management, L bought 4,200,000 shares of the company’s stock in a transaction on Wednesday, June 22nd. The stock was purchased at an average cost of $2.00 per share, for a total transaction of $8,400,000.00. The disclosure for this purchase can be found here.

Other hedge funds and institutional investors have recently modified their holdings of the company. Gamco Investors INC. ET AL raised its position in shares of BioScrip by 1.4% in the fourth quarter. Gamco Investors INC. ET AL now owns 864,850 shares of the company’s stock valued at $1,513,000 after buying an additional 12,250 shares during the last quarter. Diamond Hill Capital Management Inc. raised its position in shares of BioScrip by 2.5% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 3,055,476 shares of the company’s stock valued at $5,347,000 after buying an additional 74,757 shares during the last quarter. Finally, Gabelli Funds LLC raised its position in shares of BioScrip by 22.9% in the fourth quarter. Gabelli Funds LLC now owns 11,430,900 shares of the company’s stock valued at $20,004,000 after buying an additional 2,132,060 shares during the last quarter.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.